News roundup Monday, December 13

Xintela announces that the company has signed a Letter of Intent with the veterinary medicine company. Read more.

Exact Sciences comments on study that used the company's genetic diagnostic test Oncotype DX Breast Recurrence Score to identify which breast cancer patients are most likely to benefit from chemotherapy. Read more.

Egetis Therapeutics plans to submit an application for marketing approval for Emcitate to the European Medicines Agency based on existing clinical data. Read more.

Positive results from Sigrid Therapeutics proof-of-concept study STAR has been published in Nanomedicine. Read more.

Genmab announces that Janssen has received conditional European marketing approval for RYBREVANT. Read more.

Sobi appoints Anders Ullman appointed as new Head of R&D. Read more.

Gabriella Björknert Caracciolo has announced that she wishes to leave the CFO and vice president roles for Bactiguard Holding. Read more.

Lumito publishes Investor Letter. Read more.

2cureX announces that the 2021 launch plan goal has been reached. Read more.

Brain+ publishes update. Read more.

Exact Therapeutics will present at DNB Nordic Healthcare Conference. Read more.

Scandinavian Real Heart delisted from Spotlight Stock Market after closing on December 16. Read more.

The Analysis Guide publishes analyses of Lipigon, read more, and Promore Pharma, read more.

Notices of general meetings:

Karolinska Development

Communiqués:

ContextVision  EQL Pharma  Oxcia

News received since Friday lunch:

Karolinska Development has proposed a rights issue of approximately SEK 491 million and published a proposal for a new board member. Read more.

BioInvent International and CASI Pharmaceuticals has received CTA approval for clinical studies of BI-1206 in non-Hodgkin's lymphoma in China. Read moreBioInvent also presented updated positive interim data from its novel anti-FcγRIIB antibody BI-1206. Read more.

Immunicum presented phase II data showing reduced MRD and improved survival with DCP-001-treatment in AML patients on American Society of Hematology Annual Meeting & Exposition (ASH). Read more.

Newbury Pharmaceuticals has strengthened its oncology portfolio with Lapatinib. Read more.

The transfer of Oasmia Pharmaceuticals sales permit for Apealea to Inceptua has been formally approved. Read more.

BrainCool commented on increased support for implementing fast track reimbursement for breakthrough devices in the US. Read more.

Diagonal Bio has completed the Stage 1 audit of its Quality System (QMS) by the Notified Body (BSI). Read more.

Calmarks Rights issue is registered. Read more.

AstraZeneca presented updated phase III results at ASH current Calquence. Read more.

Seagen announced updated results from the pivotal HER2CLIMB study evaluating Tukysa in patients with HER2-positive breast cancer and brain metastases. Read more.

ContextVision announced that INIFY Laboratories becomes a separate company. Read more.

Isofol Medical has appointed Jenny Sundqvist to Chief Commercial Officer (CCO). Read more.

Targovax announced insider participation in the issue. Read moreThe company will present at DNB's Nordic Healthcare Conference. Read more.

Allarity Therapeutics announced the acceptance rate for the share exchange offer ahead of the delisting on Nasdaq First North Growth Market. Read more.

SensoDetect informed about the company's social media. Read more.

Zealand Pharma has increased its share capital. Read more.

Active Biotechs Nomination committee has been appointed. Read more.

Nanoform published financial calendar for 2022. Read more.

ArcticZymes Technologies informed about insider transactions. Read moreThe company has also increased its share capital, read more here, and informed about an insider transaction here.

This morning's winner: Elicera Therapeutics 13,3%, Invent Medic 9,8%, Xintela 9,2%, Spermosens 9,2%, Promore Pharma 9%

This morning's losers: Karolinska Development -15,7%, Nicoccino Holding -8,7%, Medimi -7,7%, Ziccum -7,7%, Abliva -6,7%

Index: OMXS30 2340 +1,06%, Healthcare +0,56%